Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults - 21/11/24
Alzheimer’s Disease Neuroimaging Initiative
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Abstract |
Background |
Identifying individuals before the onset of overt symptoms is key in the prevention of Alzheimer’s disease (AD).
Objkectives |
Investigate the use of miRNA as early blood-biomarker of cognitive decline in older adults.
Design |
Cross-sectional.
Setting |
Two observational cohorts (CHARIOT-PRO, Alzheimer’s Disease Neuroimaging Initiative (ADNI)).
Participants |
830 individuals without overt clinical symptoms from CHARIOT-PRO and 812 individuals from ADNI.
Measurements |
qPCR analysis of a prioritised set of 38 miRNAs in the blood of individuals from CHARIOT-PRO, followed by a brain-specific functional enrichment analysis for the significant miRNAs. In ADNI, genetic association analysis for polymorphisms within the significant miRNAs’ genes and CSF levels of phosphorylated-tau, total-tau, amyloid-β42, soluble-TREM2 and BACE1 activity using whole genome sequencing data. Post-hoc analysis using multi-omics datasets.
Results |
Six miRNAs (hsa-miR-128-3p, hsa-miR-144-5p, hsa-miR-146a-5p, hsa-miR-26a-5p, hsa-miR-29c-3p and hsa-miR-363-3p) were downregulated in the blood of individuals with low cognitive performance on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The pathway enrichment analysis indicated involvement of apoptosis and inflammation, relevant in early AD stages. Polymorphisms within genes encoding for hsa-miR-29c-3p and hsa-miR-146a-5p were associated with CSF levels of amyloid-β42, soluble-TREM2 and BACE1 activity, and 21 variants were eQTL for hippocampal MIR29C expression.
Conclusions |
six miRNAs may serve as potential blood biomarker of subclinical cognitive deficits in AD. Polymorphisms within these miRNAs suggest a possible interplay between the amyloid cascade and microglial activation at preclinical stages of AD.
Il testo completo di questo articolo è disponibile in PDF.Key words : miRNA, preclinical, blood-biomarker, omics, GWAS
Mappa
| Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.Loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: ADNI_Acknowledgement_List.Pdf. |
Vol 11 - N° 1
P. 230-240 - Gennaio 2024 Ritorno al numero
Articolo precedente
- The Therapeutic Effects of Noninvasive Brain Stimulation Combined with Cognitive Training in Elders with Alzheimer’s Disease or Amnesic Mild Cognitive Impairment
- J.-Y. Wang, J.-Y. Qin, J.-Y. Ye, W.-T. Li, M.-Q.-Z. Tong, Hui Ouyang, Fengxia Yan
- Are Population-Level Approaches to Dementia Risk Reduction Under-Researched? A Rapid Review of the Dementia Prevention Literature
- Sebastian Walsh, L. Wallace, I. Kuhn, O. Mytton, L. Lafortune, W. Wills, N. Mukadam, C. Brayne
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.